Blog

It has been about a month since the last earnings report for Lam Research (LRCX). Shares have added about 16.9% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue

A month has gone by since the last earnings report for Southwest Airlines (LUV). Shares have added about 8% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will

A month has gone by since the last earnings report for Las Vegas Sands (LVS). Shares have lost about 4.8% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue

A month has gone by since the last earnings report for Liberty Energy (LBRT). Shares have added about 1.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will

A month has gone by since the last earnings report for IBM (IBM). Shares have added about 9.5% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to

A month has gone by since the last earnings report for Kinder Morgan (KMI). Shares have added about 5.6% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue

It has been about a month since the last earnings report for Knight-Swift Transportation Holdings (KNX). Shares have added about 6.8% in that time frame, outperforming the S&P 500.

But investors

A month has gone by since the last earnings report for Hexcel (HXL). Shares have lost about 7.2% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent

A month has gone by since the last earnings report for Elevance Health (ELV). Shares have added about 12.6% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will

A month has gone by since the last earnings report for CSX (CSX). Shares have lost about 0.6% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading up to

A month has gone by since the last earnings report for Globe Life (GL). Shares have added about 1.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the

It has been about a month since the last earnings report for First American Financial (FAF). Shares have lost about 1.5% in that time frame, underperforming the S&P 500.

But investors have to be

It has been about a month since the last earnings report for CME Group (CME). Shares have added about 1.3% in that time frame, underperforming the S&P 500.

Will the recent positive trend continue

A month has gone by since the last earnings report for CACI International (CACI). Shares have lost about 6.9% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue

It has been about a month since the last earnings report for Boston Scientific (BSX). Shares have lost about 13% in that time frame, underperforming the S&P 500.

But investors have to be wondering

It has been about a month since the last earnings report for Boeing (BA). Shares have lost about 6.2% in that time frame, underperforming the S&P 500.

Will the recent negative trend continue leading

It has been about a month since the last earnings report for Amerisafe (AMSF). Shares have added about 0.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will

KLA Corporation’s KLAC service business is steadily evolving into one of its most dependable long-term growth drivers. During the third-quarter fiscal 2026 earnings call, management emphasized that

Flowers Foods, Inc. FLO reported first-quarter fiscal 2026 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. While net sales increased, earnings decreased from the

RF Industries, Ltd.’s RFIL thermal cooling business is emerging as one of its most promising long-term growth drivers. During the first-quarter fiscal 2026 earnings call, management highlighted

The Gap, Inc. GAP is expected to register top-line growth when it reports first-quarter fiscal 2026 results on May 28, after the closing bell. For revenues, the Zacks Consensus Estimate is pegged at

Sales of Merck’s MRK second-largest product, Gardasil, which is a vaccine approved to prevent certain cancers caused by the human papillomavirus, have been declining for some time now. While the

Keros Therapeutics KROS is recasting itself as a neuromuscular execution story, anchored by rinvatercept (KER-065) and a catalyst path that begins in 2026. The shift comes as the company leans into

Keros Therapeutics KROS is recasting itself as a neuromuscular execution story, anchored by rinvatercept (KER-065) and a catalyst path that begins in 2026. The shift comes as the company leans into

Keros Therapeutics KROS posted a messy first-quarter 2026 print, with a wider-than-expected loss and a steep revenue decline. The headline numbers look worse than the underlying operating reality